Lisata Therapeutics Inc. Completes Enrollment for iLSTA Trial, Reports Promising Preliminary Data on Certepetide in Treating Pancreatic Cancer

Reuters07-17

<a href="https://laohu8.com/S/LSTA">Lisata Therapeutics</a> Inc. Completes Enrollment for iLSTA Trial, Reports Promising Preliminary Data on Certepetide in Treating Pancreatic Cancer

Lisata Therapeutics Inc. and WARPNINE have announced the completion of patient enrollment for the Phase 1b/2a iLSTA trial in Australia. The study is evaluating Lisata's proprietary iRGD cyclic peptide product candidate, certepetide, in combination with standard-of-care chemotherapy and immunotherapy for treating locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). Preliminary data presented at ESMO-GI indicated a 60% overall response rate and a 100% overall disease control rate. Final results from the study are anticipated in the future, with the potential to offer a new treatment option for patients with locally advanced PDAC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9495724-en) on July 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2552148606?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552148606","market":"us","top_or_hot":-1,"title":"Lisata Therapeutics Inc. Completes Enrollment for iLSTA Trial, Reports Promising Preliminary Data on Certepetide in Treating Pancreatic Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a> Inc. Completes Enrollment for iLSTA Trial, Reports Promising Preliminary Data on Certepetide in Treating Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. and WARPNINE have announced the completion of patient enrollment for the Phase 1b/2a iLSTA trial in Australia. The study is evaluating Lisata's proprietary iRGD cyclic peptide product candidate, certepetide, in combination with standard-of-care chemotherapy and immunotherapy for treating locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). Preliminary data presented at ESMO-GI indicated a 60% overall response rate and a 100% overall disease control rate. Final results from the study are anticipated in the future, with the potential to offer a new treatment option for patients with locally advanced PDAC.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9495724-en) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lisata Therapeutics Inc. Completes Enrollment for iLSTA Trial, Reports Promising Preliminary Data on Certepetide in Treating Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLisata Therapeutics Inc. Completes Enrollment for iLSTA Trial, Reports Promising Preliminary Data on Certepetide in Treating Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-17 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a> Inc. Completes Enrollment for iLSTA Trial, Reports Promising Preliminary Data on Certepetide in Treating Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. and WARPNINE have announced the completion of patient enrollment for the Phase 1b/2a iLSTA trial in Australia. The study is evaluating Lisata's proprietary iRGD cyclic peptide product candidate, certepetide, in combination with standard-of-care chemotherapy and immunotherapy for treating locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). Preliminary data presented at ESMO-GI indicated a 60% overall response rate and a 100% overall disease control rate. Final results from the study are anticipated in the future, with the potential to offer a new treatment option for patients with locally advanced PDAC.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9495724-en) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL8td2G3:1","article_id":"2552148606","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552148606","pubTimestamp":1752753641,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lisata Therapeutics Inc. Completes Enrollment for iLSTA Trial, Reports Promising Preliminary Data on Certepetide in Treating Pancreatic Cancer. Lisata Therapeutics Inc. and WARPNINE have announced the completion of patient enrollment for the Phase 1b/2a iLSTA trial in Australia. The study is evaluating Lisata's proprietary iRGD cyclic peptide product candidate, certepetide, in combination with standard-of-care chemotherapy and immunotherapy for treating locally advanced non-resectable pancreatic ductal adenocarcinoma . Preliminary data presented at ESMO-GI indicated a 60% overall response rate and a 100% overall disease control rate. Final results from the study are anticipated in the future, with the potential to offer a new treatment option for patients with locally advanced PDAC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for infor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LSTA":"LISATA THERAPEUTICS INC","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","BK4585":"ETF&股票定投概念"},"translate_title":"Lisata Therapeutics Inc.完成iLSTA试验的入组，报告了Certepetide治疗胰腺癌的有希望的初步数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LSTA":0.9,"NDAQ":0.9},"content_text":"Lisata Therapeutics Inc. Completes Enrollment for iLSTA Trial, Reports Promising Preliminary Data on Certepetide in Treating Pancreatic Cancer\n    \n\n        Lisata Therapeutics Inc. and WARPNINE have announced the completion of patient enrollment for the Phase 1b/2a iLSTA trial in Australia. The study is evaluating Lisata's proprietary iRGD cyclic peptide product candidate, certepetide, in combination with standard-of-care chemotherapy and immunotherapy for treating locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). Preliminary data presented at ESMO-GI indicated a 60% overall response rate and a 100% overall disease control rate. Final results from the study are anticipated in the future, with the potential to offer a new treatment option for patients with locally advanced PDAC.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9495724-en) on July 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552148606","isCrawlerRequest":true}